ArticleBMC women's health2025
May serum advanced oxidation protein products levels be diagnostic markers in endometrioma?
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic utility of advanced oxidation protein products (AOPPs), calprotectin, and classical tumor markers (CA 125 and CA19-9) in distinguishing ovarian endometriomas from simple cysts and healthy controls, as well as to assess their predictive value for endometriomas.
methodsIn this prospective case-control study, a total of 133 women who underwent laparoscopic surgery for ovarian cystic lesions were divided into three groups: endometrioma (n = 51), simple ovarian cyst (n = 40), and control (n = 42). Serum levels of AOPP, calprotectin, CA 125, and CA19-9 were measured preoperatively. Group comparisons were performed using one-way ANOVA and Bonferroni post hoc tests. Binary logistic regression was used to identify independent predictors of endometrioma. Receiver operating characteristic (ROC) analysis was conducted to evaluate the diagnostic performance of each biomarker.
resultsSerum levels of AOPP, calprotectin, CA 125, and CA19-9 were significantly higher in the endometrioma group compared to the other groups (p < 0.001). Logistic regression analysis identified AOPP (OR = 1.329; 95% CI: 1.142-1.545), CA 125 (OR = 1.024; 95% CI: 1.008-1.040), and calprotectin (OR = 1.007; 95% CI: 1.002-1.012) as independent predictors of endometrioma. Among all biomarkers, CA 125 demonstrated the highest diagnostic accuracy (AUC = 0.864), followed by AOPP (AUC = 0.732), CA19-9 (AUC = 0.721), and calprotectin (AUC = 0.693).
conclusionSerum levels of AOPP, calprotectin, CA 125, and CA19-9 may serve as predictive biomarkers for endometrioma. However, further studies with larger sample sizes are needed to validate these findings and confirm the diagnostic utility of these biomarkers in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.